Atara Biotherapeutics, Inc.
2659 Townsgate Road
Suite 236
Thousand Oaks
California
91361
United States
152 articles with Atara Biotherapeutics, Inc.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 14, 2021
5/14/2021
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of inducement awards to Cokey Nguyen, its Senior Vice President, Chief Scientific Officer.
-
BioSpace Movers & Shakers, May 14
5/14/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers. -
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
5/13/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will participate in a fireside chat at the Cowen Virtual Oncology Innovation Summit
-
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
5/10/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today named cell therapy and oncology expert Cokey Nguyen, Ph.D. as Chief Scientific Officer.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 07, 2021
5/7/2021
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of an aggregate of 229,931 restricted stock units of Atara’s common stock to 47 newly hired employees and stock options to purchase an aggregate of 206,167 shares of Atara’s common stock to 15 such newly hired employees.
-
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
5/4/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent business highlights and key catalysts over the next 18 months.
-
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
4/27/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will release first quarter 2021 financial results after market close on Tuesday, May 4, 2021
-
BioSpace Movers & Shakers, April 9
4/9/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Apr 02, 2021 - Apr 02, 2021
4/2/2021
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 52,019 restricted stock units of Atara’s common stock to 24 newly hired employees and stock options to purchase an aggregate of 82,342 shares of Atara’s common stock to five such newly hired employees.
-
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting
3/14/2021
Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR)
-
Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference
3/9/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will participate in a fireside chat at the Virtual 33rd Annual ROTH Conference
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Mar 05, 2021
3/5/2021
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of restricted stock units to acquire 40,800 shares of common stock to ten newly hired employees and stock options to purchase an aggregate of 55,000 shares of common stock to four such newly hired employees.
-
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
2/18/2021
Live Conference Call and Webcast at 4:30 p.m. EST
-
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
2/8/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the presentation of data supporting the proposed mechanism of action of their lead product candidate, tabelecleucel (tab-cel®), and five additional poster presentations at the Transplantation & Cellular Therapy (TCT) Meeting
-
Atara Chief Executive Officer Pascal Touchon believes the positive momentum will continue for his company through the coming months of 2021.
-
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
1/19/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will present data in the form of six poster presentations at the Transplantation & Cellular Therapy
-
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
1/10/2021
Atara has had productive interactions with the FDA for ATA188 and is progressing the Phase 2 randomized clinical trial (RCT) toward an interim analysis in H1 2022
-
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/6/2021
Atara Biotherapeutics to Present at the 39 th Annual J.P. Morgan Healthcare Conference
-
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
1/4/2021
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel ® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Company to Host Conference Call on January 4 th at 8:30 a.m. EST
-
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
12/9/2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock at a price to the public of $24.50 per share